Pharmaceutical company GlaxoSmithKline reported a 3.5 percent drop in third-quarter earnings Thursday due to generic competition and a European ban on its diabetes drug Avandia, which was also restricted in the United States.
MiamiHerald.com: Business, Miami Herald: Business
Thu, 10/21/2010 - 5:43am
Pharmaceutical company GlaxoSmithKline reported a 3.5 percent drop in third-quarter earnings Thursday due to generic competition and a European ban on its diabetes drug Avandia, which was also restricted in the United States.